Supplementary Figures from Preexisting Immunity Drives the Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma

Supplementary Figures S1 to S14 Supplementary Figure 1. Multidimensional analysis of baseline EAC tumor and blood samples Supplementary Figure 2. Baseline higher immune gene signatures and reduced resistance to stress are associated with response to neoadjuvant chemotherapy. Supplementary Figure 3. Immunohistochemistry for Foxp3, CD163, CD45RO performed on treatment-naïve EACs Supplementary Figure 4. Immunohistochemistry on treatment-naïve EACs for CD3, CD4, CD8 and CD68 Supplementary Figure 5. Digital spatial profiling of the proteome in treatment-naïve EACs Supplementary Figure 6. Panels for flow cytometry analysis of T lymphocytes Supplementary Figure 7. High-dimensional flow cytometry analysis of CD4+ tumorinfiltrating lymphocytes Supplementary Figure 8. High-dimensional flow cytometry analysis of CD8+ tumorinfiltrating lymphocytes Supplementary Figure 9. Panels showing flow cytometry analysis of CD3- immune cell subsets Supplementary Figure 10. High-dimensional flow cytometry analysis of tumor-infiltrating CD45+CD3- cells Supplementary Figure 11. High-dimensional flow cytometry analysis of circulating CD4+ lymphocytes Supplementary Figure 12. High-dimensional flow cytometry analysis of circulating CD8+ lymphocytes Supplementary Figure 13. High-dimensional flow cytometry analysis of circulating CD45+CD3- cells Supplementary Figure 14. Concentrations of plasma cytokines in EAC patients before neoadjuvant chemotherapy